A long awaited Australian Senate committee report into gene patenting has recently been released, providing totally inconclusive results, meaning the status quo on gene patents is maintained for now. The terms of reference for the inquiry directed the Committee to consider the impacts of gene patents on healthcare, medical research and the health and wellbeing of Australians.

A Principal from Shelston IP discusses the current issues surrounding patent law and the pharmaceutical industry.

IP Australia provides a streamlined process for requesting an extension of time for delays caused by the COVID-19 crisis.

Following from the recent political partisanship in the US there has been a shutdown of non-essential government services.

The issue of New Jersey Transit failing to register its trade marks, logo and slogan is a reminder to audit IP assets.

This is a submission to the Senate Committee which is considering changes to the Government's R&D tax incentive regime.

The CNIPA-IPONZ PPH pilot program commenced on 1 November 2024.

China boasts a prominent and innovative IP market, and homes one of IPH's largest offices.

The government issued a new regulation to remove ability of patent owners to postpone working their patented inventions.

Friday the 13th proved lucky for those opposed to gene patents in Australia.

Adoption of US-style fair use provisions in copyright law could spur new types of cloud computing services in Australia.

Australian patent applicants and patentees will have to continue to adapt to the law as set out in previous decisions.

Australia's Federal Court has thwarted a trade mark owner's attempts to use a shape trade mark to extend monopoly protection for a utilitarian product.